www.statnews.com Open in urlscan Pro
2606:4700::6812:1ccd  Public Scan

Form analysis
3 forms found in the DOM

GET https://www.statnews.com/

<form class="header-search search-form" role="search" method="get" action="https://www.statnews.com/">
  <input type="search" class="search-form-field" placeholder="Search …" value="" name="s" aria-label="Search …">
  <input type="hidden" name="search_sort" value="{&quot;field&quot;:[&quot;relevance&quot;],&quot;order&quot;:[&quot;desc&quot;]}">
  <button type="submit" class="header-btn header-btn-search">Search</button>
</form>

Name: page — POST /wp-json/stat-hubspot/v1/signup

<form class="stat-hubspot-signup stat-form" method="post" action="/wp-json/stat-hubspot/v1/signup" name="page">
  <div class="stat-hubspot-signup-fields">
    <div class="stat-form-inline" data-stat-newsletter-no-step-2="">
      <div class="stat-form-full">
        <input type="email" name="email" placeholder="Email Address" aria-label="Enter your email" required="">
        <div class="stat-field-error">Please enter a valid email address.</div>
        <input type="submit" value="Sign Up">
        <input type="hidden" name="stat_newsletters_source" value="homepage_widget">
        <input type="hidden" name="lists[stat_newsletters]" value="morning_rounds">
      </div>
      <div class="stat-form-full stat-form-checkbox-wrapper">
        <input type="checkbox" name="marketing_opt_in" id="marketing" value="1">
        <label for="marketing">I'd like to be emailed about new content, events, and products.</label>
      </div>
    </div>
  </div>
  <div class="stat-hubspot-signup-response"></div>
</form>

Name: default — POST /wp-json/stat-hubspot/v1/signup

<form class="stat-hubspot-signup stat-form" method="post" action="/wp-json/stat-hubspot/v1/signup" name="default">
  <div class="stat-hubspot-signup-fields">
    <input type="email" name="email" placeholder="Enter your email" aria-label="Enter your email" required="">
    <button class="stat-arrow-submit" aria-label="Submit">
      <span class="far fa-arrow-right" aria-hidden="true"></span>
    </button>
    <input type="hidden" name="stat_newsletters_source" value="footer_bar">
    <input type="hidden" name="stat_newsletters_campaign" value="">
    <input type="hidden" name="lists[stat_newsletters]" value="morning_rounds">
  </div>
  <div class="stat-hubspot-signup-response"></div>
</form>

Text Content

Skip to Main Content
Explore what it takes to make the health care system work.
research
Hospitals
Physicians
Breakthrough Summit West in San Francisco: Early bird tickets are live!
 * Newsletters
 * Log In
 * My Account
 * Subscribe Now

My Account
 * Settings
 * Billing
 * Log In

Reporting from the frontiers of health and medicine
 * Newsletters
 * Log In
 * My Account
 * Subscribe Now

 * Biotech
 * Pharma
 * Public Health
 * Health Tech
 * Policy
 * Science
 * First Opinion
 * STAT+
 * STAT Events
 * 


Search
 * Log In
 * Subscribe Now
 * My Account

Home

News
 * Latest
 * Business
   * Biotech
   * Pharma
   * Health Tech
   * Health Insurance
   * Hospitals
   * Medical Devices
 * Washington
   * Policy
   * FDA
   * CDC
   * NIH
 * Science
   * CRISPR
   * Gene Therapy
   * Research
   * Neuroscience

 * Public Health
   * Addiction
   * Covid-19
   * Abortion
   * Health Disparities
   * Infectious Disease
   * Mental Health
 * Disease
   * Cancer
   * Cardiovascular Disease
   * Chronic Disease
   * Diabetes
   * Dementia
   * Obesity
 * Features
   * The Obesity Revolution
   * Living With
   * Death Sentence

Newsletters
Opinion
Columns
 * Adam Feuerstein
 * Matthew Herper
 * Jennifer Adaeze Okwerekwu
 * Ed Silverman

Reports
E-books
Podcasts
Tools & Trackers
 * CRISPR Trackr
 * Breakthrough Device Tracker
 * Generative AI Tracker
 * Obesity Drug Tracker

Events
 * Breakthrough Summit East
 * Breakthrough Summit West

Community
 * STAT+ Connect
 * 2024 STATUS List

Video
Advertise
 * STAT Brand Studio

Don't miss out

Subscribe to STAT+ today, for the best life sciences journalism in the industry

Learn more


STAT — REPORTING FROM THE FRONTIERS OF HEALTH AND MEDICINE


LATEST

 * 2 hr ago
   
   
   NOVO NORDISK’S DIABETES DRUG OZEMPIC CUTS RISK OF KIDNEY DISEASE PROGRESSION,
   TRIAL SHOWS

 * 16 hr ago
   
   
   FIRST OVER-THE-COUNTER BIRTH CONTROL PILL IN U.S. BEGINS SHIPPING TO STORES

 * 17 hr ago
   
   
   COVID-19 INCREASES RISK OF DEVELOPING AUTOIMMUNE DISEASE, BUT VACCINATION
   HELPS, LARGE STUDY SHOWS

 * 
 * 17 hr ago
   
   
   WHITE HOUSE IS TOLD THE BIG THREE PBMS ARE ‘EVERYTHING WRONG WITH THIS
   INDUSTRY’

 * 21 hr ago
   
   
   ‘IT’S A NIGHTMARE’: ONE OF THE MOST COMMON CHILDREN’S ASTHMA MEDS IS NO
   LONGER AVAILABLE, LEAVING FAMILIES SCRAMBLING

 * 21 hr ago
   
   
   WHITE HOUSE TOUTS INCREMENTAL STEP IN MEDICARE DRUG PRICE NEGOTIATION:
   COUNTEROFFERS

More Stories


DON'T MISS

Join fellow industry leaders in NYC this March for Breakthrough Summit East

Learn more


TOP STORIES

The War on Recovery


HOW THE U.S. IS SABOTAGING ITS BEST TOOLS TO PREVENT DEATHS IN THE OPIOID
EPIDEMIC

A STAT investigation shows that virtually every sector of society obstructs the
use of methadone and buprenorphine to treat opioid addiction.

By Lev Facher

5 hr ago

 * addiction

 * opioids

 * patients

By Lev Facher

The War on Recovery
The War on Recovery 5 hr ago


STAT PLUS: Q&A: NORA VOLKOW ON HOW TO GET ‘AT LEAST 50% LESS PEOPLE DYING’ FROM
OPIOID OVERDOSE

By Lev Facher

The War on Recovery
The War on Recovery 5 hr ago


WATCH: WHY FENTANYL WITHDRAWAL IS AGONY AND HOW MEDICATION CAN PREVENT IT

By Alex Hogan


First Opinion
First Opinion 5 hr ago


HOW IDEAS FROM ANCIENT GREECE LIKE ‘A BUN IN THE OVEN’ CONTINUE TO AFFECT
REPRODUCTIVE HEALTH POLICY

By Kathleen M. Crowther

Health tech
Health tech 5 hr ago


Q&A: MICROSOFT RESEARCH HEAD EXPLAINS HOW GENERATIVE AI COULD HELP DOCTORS BE
MORE HUMAN

By Nicholas St. Fleur




MOST READ

In the Lab


FETAL CELL ORGANOIDS GROWN FROM AMNIOTIC FLUID, STUDY FINDS

1 of 5 most read today

In the Lab


COVID-19 INCREASES RISK OF AUTOIMMUNE DISEASE

2 of 5 most read today

Health


COVID ISOLATION GUIDANCE EASED BY THE CDC

3 of 5 most read today

Health


CDC PANEL: PEOPLE 65 AND OLDER SHOULD GET A COVID SPRING BOOSTER SHOT

4 of 5 most read today

Don't Miss


VOTE NOW IN STAT MADNESS 2024

5 of 5 most read today


MOST READ IN STAT+

Insurance


STAT PLUS: CHANGE HEALTHCARE: WHAT IS IT, WHY DOES ITS CYBERATTACK MATTER?

1 of 5 most read today

Exclusive


STAT PLUS: FOGPHARMA RAISES $145 MILLION IN RARE SERIES E ROUND

2 of 5 most read today

Pharmalot


STAT PLUS: WHITE HOUSE IS TOLD BIG THREE PBMS ARE 'EVERYTHING WRONG WITH THIS
INDUSTRY'

3 of 5 most read today

Biotech


STAT PLUS: $1 BILLION PROPOSAL TO GROW BOSTON, MASSACHUSETTS BIOTECH

4 of 5 most read today

Biotech


STAT PLUS: FAMILIES LOOK FOR REPLACEMENT FOR GSK ASTHMA DRUG FLOVENT

5 of 5 most read today


SPONSORED

Advertisement




FIRST OPINION

 * First Opinion
   
   
   HOW IDEAS FROM ANCIENT GREECE LIKE ‘A BUN IN THE OVEN’ CONTINUE TO AFFECT
   REPRODUCTIVE HEALTH POLICY

 * First Opinion
   
   
   MISSING DATA IS MAKING IT DIFFICULT FOR THE PHARMACEUTICAL INDUSTRY TO HELP
   LGBTQ+ PEOPLE

 * 
 * First Opinion
   
   
   TOO MANY DONOR ORGANS GO TO WASTE. HERE’S HOW TO GET THEM INTO THE PATIENTS
   WHO NEED THEM

All First Opinion


STAT+


YOUR GO-TO SOURCE FOR THE WORLD OF LIFE SCIENCES, MEDICINE, AND BIOPHARMA.
SUBSCRIBE NOW.

Cancel anytime.

Subscribe now


TRENDING NOW

All STAT+ Stories


EXPLAINING CHANGE HEALTHCARE AND THE GRAVITY OF ITS CYBERATTACK


CHANGE HEALTHCARE CYBERATTACK OUTAGE COULD PERSIST FOR WEEKS, UNITEDHEALTH GROUP
EXECUTIVE SUGGESTS


WHY WON’T MEDICARE DELIVER FOOD TO SICK SENIORS, IF IT COULD GET THEM HEALTHY?


WHITE HOUSE IS TOLD THE BIG THREE PBMS ARE ‘EVERYTHING WRONG WITH THIS INDUSTRY’

All STAT+ Stories
All Events

More From STAT

More From STAT

More From STAT


EVENTS

STAT offers a variety of in-person and virtual events throughout the year.

All Events

21

Mar


2024 STAT BREAKTHROUGH SUMMIT EAST

New York, NY March 21, 2024

At the first STAT Summit of 2024, we're delving into what it really means to
focus on patients across biotech, health tech, and R&D.

29

Apr


STAT IN DC: POLICY IN HEALTH CARE

Washington, DC

16

May


2024 STAT BREAKTHROUGH SUMMIT WEST

San Francisco, CA

14

Mar


MARCH OF THE BIOSIMILARS

Virtual

All Events



MORE STORIES

 * Latest
 * Most Read
 * Subscriber Only
 * Opinion
 * 

Pharma
Pharma 2 hr ago


STAT PLUS: NOVO NORDISK’S DIABETES DRUG OZEMPIC CUTS RISK OF KIDNEY DISEASE
PROGRESSION, TRIAL SHOWS

By Andrew Joseph • 2 hr ago

Health
Health 16 hr ago


FIRST OVER-THE-COUNTER BIRTH CONTROL PILL IN U.S. BEGINS SHIPPING TO STORES

By Associated Press • 16 hr ago

In the Lab
In the Lab 17 hr ago


COVID-19 INCREASES RISK OF DEVELOPING AUTOIMMUNE DISEASE, BUT VACCINATION HELPS,
LARGE STUDY SHOWS

By Isabella Cueto • 17 hr ago

Pharmalot
Pharmalot 17 hr ago


STAT PLUS: WHITE HOUSE IS TOLD THE BIG THREE PBMS ARE ‘EVERYTHING WRONG WITH
THIS INDUSTRY’

By Ed Silverman • 17 hr ago

Biotech
Biotech 21 hr ago


STAT PLUS: ‘IT’S A NIGHTMARE’: ONE OF THE MOST COMMON CHILDREN’S ASTHMA MEDS IS
NO LONGER AVAILABLE, LEAVING FAMILIES SCRAMBLING

By Jason Laughlin — Boston Globe • 21 hr ago

Politics
Politics 21 hr ago


STAT PLUS: WHITE HOUSE TOUTS INCREMENTAL STEP IN MEDICARE DRUG PRICE
NEGOTIATION: COUNTEROFFERS

By Rachel Cohrs • 21 hr ago

Biotech
Biotech 22 hr ago


STAT PLUS: MASSACHUSETTS LAWMAKERS CONSIDER $1 BILLION PROPOSAL TO BOLSTER
REGION’S LIFE SCIENCE LEADERSHIP

By Robert Weisman — Boston Globe • 22 hr ago

In the Lab
In the Lab 23 hr ago


IN A FIRST, FETAL CELL ORGANOIDS GENERATED FROM AMNIOTIC FLUID, NEW STUDY
REPORTS

By Deborah Balthazar • 23 hr ago


The Readout
The Readout 1 day ago


SERUM INSTITUTE OF INDIA WANTS GOVERNMENT HPV CONTRACT

By Meghana Keshavan • 1 day ago

Health
Health 1 day ago


STAT PLUS: HE’S 19 MONTHS OLD AND HAS ONE OF THE WORLD’S RAREST DISEASES. HIS
PARENTS ARE DETERMINED TO FIND A CURE.

By Jonathan Saltzman — Boston Globe • 1 day ago

Biotech
Biotech 1 day ago


STAT PLUS: LONGER TREATMENT GAVE BETTER LIVER OUTCOMES FOR MASH PATIENTS, AKERO
DRUG STUDY SHOWS

By Adam Feuerstein • 1 day ago

First Opinion
First Opinion 1 day ago


MISSING DATA IS MAKING IT DIFFICULT FOR THE PHARMACEUTICAL INDUSTRY TO HELP
LGBTQ+ PEOPLE

By Paul Shay • 1 day ago

Health tech
Health tech 1 day ago


STAT PLUS: FEDERAL REGULATORS, SCRAMBLING TO KEEP UP WITH AI IN HEALTH CARE,
TEAM UP WITH INDUSTRY TO SET STANDARDS

By Casey Ross • 1 day ago

All Stories
The War on Recovery
The War on Recovery 5 hr ago


HOW THE U.S. IS SABOTAGING ITS BEST TOOLS TO PREVENT DEATHS IN THE OPIOID
EPIDEMIC

By Lev Facher • 5 hr ago

Pharma
Pharma 2 hr ago


STAT PLUS: NOVO NORDISK’S DIABETES DRUG OZEMPIC CUTS RISK OF KIDNEY DISEASE
PROGRESSION, TRIAL SHOWS

By Andrew Joseph • 2 hr ago

Exclusive
Exclusive 1 week ago


MD ANDERSON TRIED — AND FAILED — TO RESOLVE RESEARCH CREDIT DISPUTE BETWEEN TWO
SCIENTISTS, NEW DOCUMENTS SHOW

By Angus Chen • 1 week ago

The War on Recovery
The War on Recovery 5 hr ago


WATCH: WHY FENTANYL WITHDRAWAL IS AGONY AND HOW MEDICATION CAN PREVENT IT

By Alex Hogan • 5 hr ago

First Opinion
First Opinion 6 days ago


MEDICARE ADVANTAGE IS BAD FOR PATIENTS AND BAD FOR INVESTORS

By Wendell Potter and Philip Verhoef • 6 days ago

Politics
Politics 21 hr ago


STAT PLUS: WHITE HOUSE TOUTS INCREMENTAL STEP IN MEDICARE DRUG PRICE
NEGOTIATION: COUNTEROFFERS

By Rachel Cohrs • 21 hr ago

Pharmalot
Pharmalot 13 min ago


STAT PLUS: PHARMALITTLE: WE’RE READING ABOUT OZEMPIC TACKLING KIDNEY DISEASE,
OTC BIRTH CONTROL, AND MORE

By Ed Silverman • 13 min ago

Pharmalot
Pharmalot 1 day ago


STAT PLUS: PHARMALITTLE: WE’RE READING ABOUT A NIXED MEDICARE NEGOTIATION
LAWSUIT, AN OBAMACARE CHALLENGE, AND MORE

By Ed Silverman • 1 day ago

Health tech
Health tech 1 day ago


STAT PLUS: MEDICARE IS A TRICKY MARKET FOR TELEHEALTH COMPANIES. WHY IS
TALKSPACE BETTING ON IT?

By Mario Aguilar • 1 day ago

Insurance
Insurance 1 day ago


STAT PLUS: EXPLAINING CHANGE HEALTHCARE AND THE GRAVITY OF ITS CYBERATTACK

By Bob Herman • 1 day ago

Politics
Politics 2 days ago


STAT PLUS: CONGRESS GIVES DOCTORS MEDICARE PAY BUMP, SETS UP DECEMBER FIGHT IN
NEW FUNDING PACKAGE

By John Wilkerson and Rachel Cohrs • 2 days ago

Hospitals
Hospitals 4 days ago


STAT PLUS: RADONDA VAUGHT, NURSE WHO ACCIDENTALLY KILLED PATIENT, TO SPEAK AT
COMMONSPIRIT EVENT ON PATIENT SAFETY

By Tara Bannow • 4 days ago

First Opinion
First Opinion 4 days ago


NEW FEDERAL GUIDANCE IS HURTING CANCER PATIENTS, ESPECIALLY THOSE IN RURAL AREAS

By Samyukta Mullangi • 4 days ago

Adam's Take
Adam's Take 5 days ago


STAT PLUS: AN INSIDE LOOK AT PIPES, THE FINANCING TREND THAT HAS BIOTECH ABUZZ

By Adam Feuerstein • 5 days ago

First Opinion
First Opinion 6 days ago


MEDICARE ADVANTAGE IS BAD FOR PATIENTS AND BAD FOR INVESTORS

By Wendell Potter and Philip Verhoef • 6 days ago

First Opinion
First Opinion 1 week ago


IVF BANS LIKE ALABAMA’S COULD COST THE LIVES OF CHILDREN ALREADY BORN

By Allen Goldberg • 1 week ago

First Opinion
First Opinion 1 week ago


PALLIATIVE PSYCHIATRY OFFERS A NEW PATH FOR SOME PEOPLE WITH SERIOUS MENTAL
ILLNESS

By Anand Kumar • 1 week ago

First Opinion
First Opinion 1 week ago


A NEW LOUISIANA CAPITAL-PUNISHMENT BILL WOULD FUNDAMENTALLY ALTER PHYSICIAN
LICENSING

By Joel B. Zivot • 1 week ago


NEWSLETTERS

Mon - Fri

Your daily dose of news in health and science

Elizabeth Cooney

Please enter a valid email address.
I'd like to be emailed about new content, events, and products.


Our Picks

Our Picks


OUR PICKS

STAT’s selection of must-read stories and investigations


INTRODUCING THE 2024 STATUS LIST, THE DEFINITIVE ACCOUNTING OF LEADERS IN THE
LIFE SCIENCES

By STAT Staff


STAT PLUS: AI CAN SPEED UP DRUG DISCOVERY BUT DON’T EXPECT IT TO CURE CANCER,
YET

By Casey Ross


STAT PLUS: FROM A SMALL TOWN IN WALES, A SCIENTIFIC SLEUTH HAS SHAKEN
DANA-FARBER — AND ELEVATED THE ISSUE OF RESEARCH INTEGRITY

By Andrew Joseph


STAT PLUS: CAN WEGOVY TREAT DEPRESSION AS WELL AS OBESITY? NEW RESEARCH LOOKS TO
GLP-1 DRUGS FOR MENTAL ILLNESSES

By Elaine Chen


STAT PLUS: A JUNIOR SCIENTIST. A PROMINENT ONCOLOGIST. NOW, A CLASH AT MD
ANDERSON OVER WHO GETS RESEARCH CREDIT

By Angus Chen and Jonathan Wosen


STAT PLUS: PRICEY SICKLE CELL TREATMENTS RAISE DAUNTING NEW CHALLENGES FOR
MEDICAID PROGRAMS

By Ed Silverman


STAT PLUS: HHS LEAVES VACANT MORE THAN HALF THE SLOTS ON A KEY VACCINE ADVISORY
PANEL

By Helen Branswell


STAT PLUS: HEALTH CARE DEVELOPERS ARE IMPRESSED BY APPLE VISION PRO, BUT THEY
AREN’T DIVING HEAD FIRST

By Mario Aguilar


BIOTECH

Biotech


STAT PLUS: HERE ARE THE CANCER DRUGS PFIZER THINKS COULD REIGNITE INVESTORS’
INTEREST

By Matthew Herper

5 days ago

By Matthew Herper

Biotech
Biotech 5 days ago


STAT PLUS: HERE ARE THE CANCER DRUGS PFIZER THINKS COULD REIGNITE INVESTORS’
INTEREST

Biotech
Biotech 5 days ago


STAT PLUS: THIS CHEMIST’S LAST STARTUP SOLD FOR $4 BILLION. NOW INVESTORS HAVE
POURED $173 MILLION INTO HER NEXT ACT

Biotech
Biotech 5 days ago


STAT PLUS: Q&A: A BIOTECH VC LEADER SHARES HER NEXT BIG BETS


PHARMA

Pharmalot


STAT PLUS: MANY COSTLY GENERIC DRUGS ARE UNAVAILABLE AT AMAZON, CUBAN, AND OTHER
ALTERNATIVE PHARMACIES

By Ed Silverman

4 days ago

By Ed Silverman

Pharmalot
Pharmalot 4 days ago


STAT PLUS: MANY COSTLY GENERIC DRUGS ARE UNAVAILABLE AT AMAZON, CUBAN, AND OTHER
ALTERNATIVE PHARMACIES

Pharmalot
Pharmalot 4 days ago


STAT PLUS: UP AND DOWN THE LADDER: THE LATEST COMINGS AND GOINGS

Pharmalot
Pharmalot 4 days ago


STAT PLUS: PHARMALITTLE: WE’RE READING ABOUT RSV VAX LINK TO GSB, A PFIZER
DONATION, AND MORE


HEALTH

Health


CVS AND WALGREENS PLAN TO START DISPENSING ABORTION PILL MIFEPRISTONE SOON

By Associated Press

4 days ago

By Associated Press

Health
Health 4 days ago


CVS AND WALGREENS PLAN TO START DISPENSING ABORTION PILL MIFEPRISTONE SOON

Health
Health 4 days ago


Q&A: AMA’S CHIEF HEALTH EQUITY OFFICER ON RIDDING MEDICINE OF RACIAL
ESSENTIALISM

Health
Health 5 days ago


MORE THAN 1 BILLION PEOPLE HAVE OBESITY, INCLUDING 159 MILLION YOUNG PEOPLE,
STUDY ESTIMATES


POLITICS

Politics


STAT PLUS: FEDERAL JUDGE RULES AGAINST ASTRAZENECA IN LAWSUIT CHALLENGING
MEDICARE DRUG PRICE NEGOTIATION

By Rachel Cohrs

4 days ago

By Rachel Cohrs

Politics
Politics 4 days ago


STAT PLUS: FEDERAL JUDGE RULES AGAINST ASTRAZENECA IN LAWSUIT CHALLENGING
MEDICARE DRUG PRICE NEGOTIATION

Politics
Politics 5 days ago


STAT PLUS: WHAT DOES AMERICA’S CRACKDOWN ON CHINESE FIRMS MEAN FOR THE U.S.
BIOTECH SECTOR?

Politics
Politics 6 days ago


STAT PLUS: BIDEN ‘CONTINUES TO BE FIT FOR DUTY,’ HIS DOCTOR SAYS, AFTER
PRESIDENT UNDERGOES ANNUAL PHYSICAL


VIDEO

The War on Recovery


WATCH: WHY FENTANYL WITHDRAWAL IS AGONY AND HOW MEDICATION CAN PREVENT IT

In the Lab


WHAT IS IN UTERO GENE EDITING?

A STAT Documentary


TREATING RURAL AMERICA: THE TELEHEALTH SOLUTION

STAT Wunderkinds


A CONVERSATION WITH THE 2023 STAT WUNDERKINDS

All Videos

in The Lab

in The Lab

You hear it, and I’ve seen it. It’s publish or perish. These expectations get
higher and higher, and you can get intentional or unintentional slippage.Read
the story

— Tim Errington, Center for Open Science senior director of research

in The Lab


HEALTH TECH

Health tech


STAT PLUS: ICON ACQUIRES HUMANFIRST TO BOOST SUPPORT FOR DIGITAL TOOLS IN
CLINICAL TRIALS

By Mario Aguilar

5 days ago

By Mario Aguilar

Health tech
Health tech 5 days ago


STAT PLUS: ICON ACQUIRES HUMANFIRST TO BOOST SUPPORT FOR DIGITAL TOOLS IN
CLINICAL TRIALS

Health tech
Health tech 2 weeks ago


STAT PLUS: UNITEDHEALTH CYBERATTACK IMPEDES PHARMACIES’ AND HOSPITALS’ ABILITY
TO PROCESS INSURANCE CLAIMS

Health tech
Health tech 2 weeks ago


STAT PLUS: CLINICAL NOTES AUTOMATION STARTUP ABRIDGE RAISES $150 MILLION, TAKES
AIM AT MICROSOFT NUANCE


IN THE LAB

In the Lab


Q&A: STEM CELL BIOLOGIST PREDICTS HUMAN EMBRYO MODELS COULD PAVE THE WAY TO
ORGAN TRANSPLANTS

By Nicholas St. Fleur

1 day ago

By Nicholas St. Fleur

In the Lab
In the Lab 1 day ago


Q&A: STEM CELL BIOLOGIST PREDICTS HUMAN EMBRYO MODELS COULD PAVE THE WAY TO
ORGAN TRANSPLANTS

In the Lab
In the Lab 4 days ago


WHY DO SOME WOMEN EXPERIENCE UTI PAIN WITH NO CLEAR INFECTION? A MOUSE STUDY
OFFERS CLUES

In the Lab
In the Lab 6 days ago


‘BRAIN FOG’ IS ONE OF COVID-19’S MOST DAUNTING SYMPTOMS. A NEW STUDY MEASURES
ITS IMPACT


HOSPITALS

Hospitals


STAT PLUS: PRIVATE EQUITY FIRM OFFERS $5.8 BILLION BUYOUT OF HOSPITAL BILLING
COMPANY R1 RCM

By Bob Herman

1 week ago

By Bob Herman

Hospitals
Hospitals 1 week ago


STAT PLUS: PRIVATE EQUITY FIRM OFFERS $5.8 BILLION BUYOUT OF HOSPITAL BILLING
COMPANY R1 RCM

Hospitals
Hospitals 2 weeks ago


STAT PLUS: DOJ INVESTIGATING COMMUNITY HEALTH SYSTEMS’ HOSPITALS

Hospitals
Hospitals 3 weeks ago


STAT PLUS: SICK PATIENTS COLLAPSED WAITING FOR CARE AT MASS. HOSPITAL WITH KNOWN
SAFETY VIOLATIONS


INSURANCE

Insurance


STAT PLUS: EXPERTS SAY SCALE OF CHANGE CYBERATTACK SHOWS RISK OF CENTRALIZED
CLAIMS PROCESSING

By Brittany Trang, Tara Bannow, and Bob Herman

1 week ago

By Brittany Trang, Tara Bannow, and Bob Herman

Insurance
Insurance 1 week ago


STAT PLUS: EXPERTS SAY SCALE OF CHANGE CYBERATTACK SHOWS RISK OF CENTRALIZED
CLAIMS PROCESSING

Insurance
Insurance 3 weeks ago


STAT PLUS: MEDICARE ADVANTAGE ENROLLMENT RACES PAST 33 MILLION

Insurance
Insurance 3 weeks ago


STAT PLUS: LOUISIANA, OREGON DEALS SHOW HEALTH INSURER ACQUISITIONS AREN’T A
SURE THING ANYMORE


PODCASTS

The Readout LOUD


LEGAL INSIDER TRADING, BOOMING BIOTECH STOCKS, & THE NEXT GLP-1

The Readout LOUD


PHARMA GOES TO WASHINGTON, ALNYLAM’S FUTURE, & GILEAD’S DEALMAKING

The Readout LOUD


AI IN MEDICINE, DETANGLING HYPE, AND ICELANDIC DNA

The Readout LOUD


VERTEX’S POLARIZING DATA, ADUHELM’S ADIEU, & AN FDA ICON

All Podcasts

Sign up for our morning rounds newsletter




Reporting from the frontiers of health and medicine

Back to top

Company

 * About
 * Our Team
 * Contact Us
 * Careers
 * Diversity & Inclusion
 * Our Awards
 * Advertise With Us
 * STAT Brand Studio
 * Supporters
 * Licensing Stories

Account

 * STAT+
 * Group Subscriptions
 * FAQ
 * My Account
 * Log In
 * Subscribe

More

 * Events
 * Newsletters
 * Reports
 * App
 * Podcasts
 * Community

 * Privacy
 * Comment Policy
 * Terms
 * Do Not Sell My Data
 * ©2024 STAT

 * 
 * 
 * 
 * 
 * 
 * 
 * 

Become a STAT+ subscriber today!

Become a STAT+ subscriber today!

Unlimited access to essential biotech, medicine, and life sciences journalism

Get started

Become a STAT+ subscriber today!

Become a STAT+ subscriber today!

Your go-to source for the latest news and insights on biopharma and the life
sciences

Get started

Become a STAT+ subscriber today!

Become a STAT+ subscriber today!

Unlimited access to essential biotech, medicine, and life sciences journalism

Get started

Become a STAT+ subscriber today!

Become a STAT+ subscriber today!

Your go-to source for the latest news and insights on biopharma and the life
sciences

Get started






STAT NEWS ASKS FOR YOUR CONSENT TO USE YOUR PERSONAL DATA TO:

 * show_chart
   Personalised advertising, advertising and content measurement, audience
   research and services development
 * perm_identity
   Personalised content
 * devices
   Store and/or access information on a device

expand_moreremove
Learn more
 * 
   How can I change my choice?
 * 
   What if I don't consent?
 * 
   How does legitimate interest work?
 * 
   Do I have to consent to everything?

Your personal data will be processed and information from your device (cookies,
unique identifiers, and other device data) may be stored by, accessed by and
shared with 9 TCF vendor(s) and 1 ad partner(s), or used specifically by this
site or app.

Some vendors may process your personal data on the basis of legitimate interest,
which you can object to by managing your options below. Look for a link at the
bottom of this page or in our privacy policy where you can withdraw consent.

Consent



Manage options

arrow_back

Data preferences


MANAGE YOUR DATA

You can choose how your personal data is used. Vendors want your permission to
do the following:

TCF vendors

help_outline


STORE AND/OR ACCESS INFORMATION ON A DEVICE

Cookies, device or similar online identifiers (e.g. login-based identifiers,
randomly assigned identifiers, network based identifiers) together with other
information (e.g. browser type and information, language, screen size, supported
technologies etc.) can be stored or read on your device to recognise it each
time it connects to an app or to a website, for one or several of the purposes
presented here.

View details
Consent (8 vendors)


USE LIMITED DATA TO SELECT ADVERTISING

Advertising presented to you on this service can be based on limited data, such
as the website or app you are using, your non-precise location, your device type
or which content you are (or have been) interacting with (for example, to limit
the number of times an ad is presented to you).

View details
Consent (1 vendor)Legitimate interest (1 vendor)help_outline


CREATE PROFILES FOR PERSONALISED ADVERTISING

Information about your activity on this service (such as forms you submit,
content you look at) can be stored and combined with other information about you
(for example, information from your previous activity on this service and other
websites or apps) or similar users. This is then used to build or improve a
profile about you (that might include possible interests and personal aspects).
Your profile can be used (also later) to present advertising that appears more
relevant based on your possible interests by this and other entities.

View details
Consent (7 vendors)


USE PROFILES TO SELECT PERSONALISED ADVERTISING

Advertising presented to you on this service can be based on your advertising
profiles, which can reflect your activity on this service or other websites or
apps (like the forms you submit, content you look at), possible interests and
personal aspects.

View details
Consent (2 vendors)


CREATE PROFILES TO PERSONALISE CONTENT

Information about your activity on this service (for instance, forms you submit,
non-advertising content you look at) can be stored and combined with other
information about you (such as your previous activity on this service or other
websites or apps) or similar users. This is then used to build or improve a
profile about you (which might for example include possible interests and
personal aspects). Your profile can be used (also later) to present content that
appears more relevant based on your possible interests, such as by adapting the
order in which content is shown to you, so that it is even easier for you to
find content that matches your interests.

View details
Consent (5 vendors)


USE PROFILES TO SELECT PERSONALISED CONTENT

Content presented to you on this service can be based on your content
personalisation profiles, which can reflect your activity on this or other
services (for instance, the forms you submit, content you look at), possible
interests and personal aspects. This can for example be used to adapt the order
in which content is shown to you, so that it is even easier for you to find
(non-advertising) content that matches your interests.

View details
Consent (1 vendor)


MEASURE ADVERTISING PERFORMANCE

Information regarding which advertising is presented to you and how you interact
with it can be used to determine how well an advert has worked for you or other
users and whether the goals of the advertising were reached. For instance,
whether you saw an ad, whether you clicked on it, whether it led you to buy a
product or visit a website, etc. This is very helpful to understand the
relevance of advertising campaigns.

View details
Consent (3 vendors)Legitimate interest (3 vendors)help_outline


MEASURE CONTENT PERFORMANCE

Information regarding which content is presented to you and how you interact
with it can be used to determine whether the (non-advertising) content e.g.
reached its intended audience and matched your interests. For instance, whether
you read an article, watch a video, listen to a podcast or look at a product
description, how long you spent on this service and the web pages you visit etc.
This is very helpful to understand the relevance of (non-advertising) content
that is shown to you.

View details
Consent (2 vendors)Legitimate interest (1 vendor)help_outline


UNDERSTAND AUDIENCES THROUGH STATISTICS OR COMBINATIONS OF DATA FROM DIFFERENT
SOURCES

Reports can be generated based on the combination of data sets (like user
profiles, statistics, market research, analytics data) regarding your
interactions and those of other users with advertising or (non-advertising)
content to identify common characteristics (for instance, to determine which
target audiences are more receptive to an ad campaign or to certain contents).

View details
Consent (5 vendors)Legitimate interest (2 vendors)help_outline


DEVELOP AND IMPROVE SERVICES

Information about your activity on this service, such as your interaction with
ads or content, can be very helpful to improve products and services and to
build new products and services based on user interactions, the type of
audience, etc. This specific purpose does not include the development or
improvement of user profiles and identifiers.

View details
Consent (4 vendors)Legitimate interest (3 vendors)help_outline


ENSURE SECURITY, PREVENT AND DETECT FRAUD, AND FIX ERRORS

help_outline

Your data can be used to monitor for and prevent unusual and possibly fraudulent
activity (for example, regarding advertising, ad clicks by bots), and ensure
systems and processes work properly and securely. It can also be used to correct
any problems you, the publisher or the advertiser may encounter in the delivery
of content and ads and in your interaction with them.

View details


DELIVER AND PRESENT ADVERTISING AND CONTENT

help_outline

Certain information (like an IP address or device capabilities) is used to
ensure the technical compatibility of the content or advertising, and to
facilitate the transmission of the content or ad to your device.

View details


MATCH AND COMBINE DATA FROM OTHER DATA SOURCES

help_outline

Information about your activity on this service may be matched and combined with
other information relating to you and originating from various sources (for
instance your activity on a separate online service, your use of a loyalty card
in-store, or your answers to a survey), in support of the purposes explained in
this notice.

View details


LINK DIFFERENT DEVICES

help_outline

In support of the purposes explained in this notice, your device might be
considered as likely linked to other devices that belong to you or your
household (for instance because you are logged in to the same service on both
your phone and your computer, or because you may use the same Internet
connection on both devices).

View details


IDENTIFY DEVICES BASED ON INFORMATION TRANSMITTED AUTOMATICALLY

help_outline

Your device might be distinguished from other devices based on information it
automatically sends when accessing the Internet (for instance, the IP address of
your Internet connection or the type of browser you are using) in support of the
purposes exposed in this notice.

View details

Vendor preferences

Accept all



Confirm choices

arrow_back

Vendor preferences


CONFIRM OUR VENDORS

Vendors can use your data to provide services. Declining a vendor can stop them
from using the data you shared.

TCF vendors

help_outline


SHARETHIS, INC

Cookie duration: 390 (days).

Data collected and processed: Privacy choices, IP addresses, Users’ profiles,
Probabilistic identifiers, Device characteristics, Browsing and interaction
data, Non-precise location data, Device identifiers

more




View details | Privacy policylaunch
Consent


LOTAME SOLUTIONS, INC

Cookie duration: 274 (days).

Data collected and processed: Privacy choices, IP addresses,
Authentication-derived identifiers, Users’ profiles, Probabilistic identifiers,
Device characteristics, User-provided data, Browsing and interaction data,
Device identifiers

more

Cookie duration resets each session. Uses other forms of storage.


View details | Privacy policylaunch
Consent


LIVERAMP

Cookie duration: 365 (days).

Data collected and processed: Privacy choices, IP addresses,
Authentication-derived identifiers, Device characteristics, Browsing and
interaction data, Non-precise location data, Device identifiers

more

Cookie duration resets each session. Uses other forms of storage.


View details | Storage details | Privacy policylaunch
Consent


DYNATA LLC

Cookie duration: 365 (days).

Data collected and processed: Privacy choices, IP addresses,
Authentication-derived identifiers, Users’ profiles, Device characteristics,
User-provided data, Browsing and interaction data, Non-precise location data,
Device identifiers

more

Cookie duration resets each session.


View details | Storage details | Privacy policylaunch
Consent


EYEOTA PTE LTD

Cookie duration: 365 (days).

Data collected and processed: Privacy choices, IP addresses, Users’ profiles,
Probabilistic identifiers, Device characteristics, Non-precise location data,
Device identifiers

more

Cookie duration resets each session.


View details | Storage details | Privacy policylaunch
Consent


BOMBORA INC.

Cookie duration: 365 (days).

Data collected and processed: IP addresses, Authentication-derived identifiers,
Users’ profiles, Device characteristics, Browsing and interaction data,
Non-precise location data, Device identifiers

more

Cookie duration resets each session. Uses other forms of storage.


View details | Storage details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


ORACLE ADVERTISING

Cookie duration: 180 (days).

Data collected and processed: Privacy choices, IP addresses,
Authentication-derived identifiers, Users’ profiles, Device characteristics,
User-provided data, Browsing and interaction data, Non-precise location data,
Device identifiers

more

Uses other forms of storage.


View details | Storage details | Privacy policylaunch
Consent


GOOGLE ADVERTISING PRODUCTS

Cookie duration: 396 (days).

Data collected and processed: Privacy choices, IP addresses,
Authentication-derived identifiers, Users’ profiles, Device characteristics,
User-provided data, Browsing and interaction data, Non-precise location data,
Device identifiers

more

Uses other forms of storage.


View details | Storage details | Privacy policylaunch
ConsentLegitimate interesthelp_outline


ORACLE DATA CLOUD - MOAT

Doesn't use cookies.

Data collected and processed: IP addresses, Non-precise location data

more




View details | Privacy policylaunch
Legitimate interesthelp_outline

Ad partners

help_outline


ADSTRA

Privacy policylaunch
Consent

Accept all



Confirm choices

Close

Please review our cookie policy

We use first- and third-party cookies to customize your experience and display
advertising. By continuing to use the site, you agree to our use of cookies. If
you want to know more or opt out in whole or in part, please see our Privacy
Notice and our Cookie FAQ.

Accept No thanks